BioXcel’s SERENITY Phase 3 Trial Secures DSMB Green Light as Shares Jump 29%

Introduction

BioXcel Therapeutics Inc. (NASDAQ: BTAI) is a biopharmaceutical company based in New Haven, Connecticut, founded in 2017. The company applies artificial intelligence to develop treatments in neuroscience and immuno-oncology. Its lead clinical asset, BXCL501 (marketed as IGALMI for certain indications), is an orally dissolving film formulation of dexmedetomidine targeting symptoms of agitation in several neuropsychiatric disorders.

Corporate Structure

According to LinkedIn, BioXcel employs between 51 and 200 staff members. The organization focuses on research and development, clinical operations, artificial intelligence drug discovery, and regulatory affairs. Collaborations with Columbia University, Yale University Medical School, and the University of North Carolina at Chapel Hill support its neuroscience pipeline.

Biopharmaceutical Innovation by CDC

Developments and News

• On July 1, 2025, the company announced that it received a second recommendation from an independent Data Safety Monitoring Board (DSMB) to continue its SERENITY At-Home pivotal Phase 3 safety trial, which evaluates the acute treatment of agitation in bipolar disorders or schizophrenia.
• On July 21, 2025, BioXcel reported the completion of patient enrollment in that trial.
• On August 1, 2025, the firm filed an 8-K report with the SEC disclosing the DSMB recommendation under Item 8.01, which highlighted the trial’s ongoing progress.

Financial and Strategic Aspects

Shares of BTAI increased by 29.20% to close at $1.77 on August 4, 2025, with a trading volume of 13,299,275 shares. As of the end of Q1 2025:
• Earnings per share were –$1.50 versus an estimated –$2.72, representing a 44.85% surprise against estimates.
• The net loss decreased from –$10.86 million in Q4 2024 to –$7.25 million, reflecting a 33.20% improvement.
• Reported EBITDA was –$49.12 million.

The company continues to advance BXCL501 for acute agitation associated with dementia due to probable Alzheimer’s disease in care settings, supported by Breakthrough Therapy designation from the FDA. Fast Track designation also applies to agitation in schizophrenia, bipolar disorders, and dementia. Other pipeline programs are dependent on funding or strategic prioritization.

Market Position and Industry Context

BioXcel operates within a competitive biotechnology sector where AI-driven discovery is gaining traction. Its focus on neuropsychiatric agitation aims to address unmet medical needs. With a market capitalization of approximately $8.3 million, BTAI shares exhibit a beta coefficient of 1.73 and an annualized volatility of 33.65%. Regulatory approvals, trial results, and partnerships are expected to influence future performance. The company also faces common sector risks, including high R&D costs, regulatory challenges, and reliance on external funding.

tl;dr

On July 1 and 21, 2025, BioXcel Therapeutics obtained DSMB recommendations to continue and completed enrollment in its SERENITY At-Home Phase 3 trial for agitation in bipolar disorders and schizophrenia. The stock price increased by 29.20% to $1.77 on August 4, 2025. Q1 results showed a narrower loss and positive EPS surprise. Breakthrough Therapy and Fast Track designations support BXCL501’s clinical progression. Upcoming trial results and regulatory milestones will influence the near-term outlook.